Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Robinson, MF; Damjanov, N; Stamenkovic, B; Radunovic, G; Kivitz, A; Cox, L; Manukyan, Z; Banfield, C; Saunders, M; Chandra, D; Vincent, MS; Mancuso, J; Peeva, E; Beebe, JS

Beebe, JS (corresponding author), Pfizer Inc, 1 Portland St,Third Floor, Cambridge, MA 02139 USA.

ARTHRITIS & RHEUMATOLOGY, 2020; 72 (10): 1621

Abstract

Objective To evaluate the efficacy and safety of PF-06651600 (ritlecitinib), an irreversible inhibitor of JAK3 and the tyrosine kinase expressed in he......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索